Alzai Health Corp. Provides Update Regarding Marketing Services Agreement with Euro Digital Media

Alzai Health commits US$425,000 to a four-month digital marketing campaign, pending TSXV approval.

What the company is saying

Alzai Health Corp. (TSXV: ALZI, OTCQB: ALZIF, FSE: H2F) is updating investors on a revised marketing services agreement with Euro Digital Media Ltd. The company clarifies that the contract term is now four months or until the US$425,000 budget is exhausted, correcting a prior disclosure of a 12-month term. The entire fee, US$425,000 plus applicable taxes, will be paid in a single upfront payment before services begin. Euro Digital will deliver a comprehensive suite of digital marketing services, including campaign and ad creation, keyword research, remarketing, bid management, and landing page development. Alzai Health emphasizes that no securities will be issued as compensation and confirms Euro Digital has no ownership in the company, maintaining an arm's length relationship. The agreement is conditional on TSX Venture Exchange approval, and services will not commence until this is received. The tone is procedural, with no forward-looking claims about the impact of the campaign.

What the data suggests

The company is committing a significant one-time marketing expenditure of US$425,000 for a four-month digital campaign, with the fee paid in advance and subject to TSXV approval. No equity or options are being issued as part of the compensation, and Euro Digital has no current ownership stake in Alzai Health. The scope of services is broad, covering multiple aspects of digital marketing, but there are no disclosed performance targets, KPIs, or expected outcomes. The disclosure is complete regarding contract terms, payment structure, and counterparty relationship, but does not provide any data on historical marketing spend, prior campaign results, or anticipated ROI. The announcement is limited to this contract and does not address broader financial or operational performance.

Analysis

The announcement is a factual update on a marketing services agreement, specifying the contract term, fee, payment structure, and scope of services. The only forward-looking element is that the services will commence after TSX Venture Exchange approval, which is a standard procedural step rather than a promotional claim. There is no exaggerated language or overstatement of potential benefits; the release does not speculate on the impact of the marketing campaign or make any projections about future growth or returns. The capital outlay of US$425,000 is disclosed, but there is no attempt to frame this as transformative or to imply immediate financial benefit. The gap between narrative and evidence is minimal, as all claims are supported by disclosed facts and there are no aspirational statements. The tone is neutral and procedural, with no hype or inflation of the agreement's significance.

Risk flags

• ●The agreement is contingent on TSX Venture Exchange approval, so there is a risk that the campaign could be delayed or altered if approval is not granted or is subject to conditions.
• ●The US$425,000 fee is payable in full before services begin, exposing Alzai Health to counterparty performance risk if Euro Digital does not deliver the agreed services or if the campaign underperforms.
• ●There are no disclosed performance metrics, guarantees, or clawback provisions tied to campaign outcomes, so the effectiveness of the marketing spend cannot be independently assessed from this disclosure.

Bottom line

Alzai Health is making a substantial upfront investment in digital marketing, committing US$425,000 for a four-month campaign with Euro Digital Media Ltd., subject to TSXV approval. The contract is clear on payment, scope, and the arm's length nature of the relationship, but does not tie compensation to specific marketing results or provide any historical context for expected impact. Investors should recognize that the entire fee is at risk if the campaign fails to deliver value, as there are no disclosed safeguards or performance targets. The most important takeaway is that this is a material marketing outlay with near-term execution risk tied to regulatory approval and campaign delivery. Any future assessment of effectiveness will require disclosure of campaign outcomes or measurable business impact.

Announcement summary

(TSXV: ALZI) (OTCQB: ALZIF) (FSE: H2F) Alzai Health Corp. announced an update to its marketing services agreement with Euro Digital Media Ltd. The Services Agreement, originally disclosed as having a 12-month term, is now expected to have a four-month term or until the budget is exhausted, whichever occurs first. The Services are expected to commence following receipt of TSX Venture Exchange (TSXV) approval. Alzai Health Corp. has agreed to pay Euro Digital a fee of US$425,000, plus any applicable local taxes, for the Services. The fee is payable in a single payment prior to the commencement of the Services. Under the agreement, Euro Digital will provide services including creating campaigns, ad groups, text ads and display ads, performing detailed keyword research, developing and managing remarketing campaigns, dynamically optimizing keyword sets, conducting ongoing bid management, optimizing keyword options, coordinating with online advertisers and marketers, placing display advertisements, and creating landing pages for advertising campaigns. No securities will be issued to Euro Digital as compensation for its marketing services. As of the date of the announcement, Euro Digital and its principal do not own any securities of Alzai Health Corp. and maintain an arm's length relationship with the company. The Services Agreement is subject to the approval of the TSX Venture Exchange. Hayim Raclaw is the Chairman and Chief Executive Officer of Alzai Health Corp.

Disagree with this article?